Upexi Future Growth

Future criteria checks 0/6

Upexi is forecast to grow earnings and revenue by 92.9% and 7% per annum respectively while EPS is expected to grow by 95.8% per annum.

Key information

92.9%

Earnings growth rate

95.8%

EPS growth rate

Personal Products earnings growth	23.8%
Revenue growth rate	7.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Feb 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:UPXI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2025	102	-4	N/A	N/A	1
6/30/2024	94	-7	N/A	N/A	1
12/31/2023	92	-20	-7	-6	N/A
9/30/2023	97	-14	-1	0	N/A
6/30/2023	81	-15	-1	0	N/A
3/31/2023	72	-3	1	1	N/A
12/31/2022	52	-1	1	2	N/A
9/30/2022	30	-7	-9	-4	N/A
6/30/2022	23	-6	-6	0	N/A
3/31/2022	24	-1	-2	5	N/A
12/31/2021	26	0	-1	5	N/A
9/30/2021	25	3	3	4	N/A
6/30/2021	24	3	2	3	N/A
3/31/2021	16	0	0	0	N/A
12/31/2020	11	-3	-2	-2	N/A
9/30/2020	9	-5	-4	-3	N/A
6/30/2020	7	-5	-6	-4	N/A
6/30/2019	2	-1	-1	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: UPXI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UPXI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UPXI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: UPXI's revenue (7% per year) is forecast to grow slower than the US market (8.1% per year).

High Growth Revenue: UPXI's revenue (7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if UPXI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Upexi Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Recent updates

New major risk - Market cap size

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

This Analyst Just Downgraded Their Upexi, Inc. (NASDAQ:UPXI) EPS Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog Supplements

Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.

Upexi, Inc. (NASDAQ:UPXI) Doing What It Can To Lift Shares

Upexi, Inc., Annual General Meeting, Jun 26, 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Upexi, Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

CEO, President & Chairman of the Board recently bought US$73k worth of stock

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.

Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.

Upexi, Inc. Files Patent for its Single Click-to-optin Technology

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Upexi, Inc. Appoints Anthony Bazan as Chief Operating Officer

Investor sentiment deteriorated over the past week

Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.

Investor sentiment improved over the past week

Grove CEO provides company update on sales and beyond

Investor sentiment improved over the past week

Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.

Grove, Inc., Annual General Meeting, May 24, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)

Investor sentiment improved over the past week

Why Grove's (NASDAQ:GRVI) Earnings Are Weaker Than They Seem

Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)

Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.

Grove: An Underrated CBD Player

Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation.

Grove, Inc. has completed an IPO in the amount of $11 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies